Tech Company Financing Transactions
ALDEA Pharma Funding Round
On 8/25/2014, ALDEA Pharma raised $24 million in Series B funding from Canaan Partners, Correlation Ventures and RusnanoMedInvest.
Transaction Overview
Company Name
Announced On
8/25/2014
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Series B
Investors
Proceeds Purpose
The financing will be used to advance Aldea's lead drug candidate, AD-6626, into clinical trials, including evaluating proof-of-concept for the treatment of subjects with acute alcohol intoxication and funding subsequent Phase 2 trials of intravenous (IV) AD-6626 in an emergency room (ER) setting. In addition, Aldea is studying oral AD-6626 for the treatment of subjects with the rare genetic disease Fanconi anemia, and anticipates the financing will support a Phase 1/2 proof-of-biology study in that indication.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3696 Haven Ave. C
Redwood City, CA 94566
USA
Redwood City, CA 94566
USA
Phone
Website
Email Address
Overview
ALDEA Pharmaceuticals develops small-molecule modulators of the ALDH family for the treatment of toxic aldehyde-related diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Yelle
Chief Medical Officer
Richard Shames
VP - R & D
Wenjin Yang
Browse more venture capital transactions:
Prev: 8/25/2014: Fairwaves venture capital transaction
Next: 8/25/2014: MedShape venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs